These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28036293)

  • 1. A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition.
    Bai J; Na H; Hua X; Wei Y; Ye T; Zhang Y; Jian G; Zeng W; Yan L; Tang Q
    Oncotarget; 2017 Jan; 8(4):6929-6939. PubMed ID: 28036293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
    Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
    Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P
    Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
    Hyrina A; Olmstead AD; Steven P; Krajden M; Tam E; Jean F
    EBioMedicine; 2017 Sep; 23():68-78. PubMed ID: 28864162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.
    Xu X; Dong Y; Ma N; Kong W; Yu C; Gong L; Chen J; Ren J
    Metabolism; 2021 Jun; 119():154768. PubMed ID: 33775647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
    Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.